4,470 IDEXX Laboratories, Inc. $IDXX Shares Sold by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,230 shares of the company’s stock after selling 4,470 shares during the period. Factory Mutual Insurance Co.’s holdings in IDEXX Laboratories were worth $21,530,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in IDXX. Arlington Trust Co LLC grew its stake in shares of IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after buying an additional 19 shares during the period. Bell Investment Advisors Inc increased its holdings in shares of IDEXX Laboratories by 45.5% during the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock worth $33,000 after buying an additional 20 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC increased its holdings in shares of IDEXX Laboratories by 21.4% during the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock worth $67,000 after buying an additional 21 shares during the last quarter. Arlington Capital Management Inc. raised its position in shares of IDEXX Laboratories by 4.8% in the 1st quarter. Arlington Capital Management Inc. now owns 479 shares of the company’s stock worth $269,000 after buying an additional 22 shares during the period. Finally, Valeo Financial Advisors LLC raised its position in shares of IDEXX Laboratories by 6.4% in the 2nd quarter. Valeo Financial Advisors LLC now owns 383 shares of the company’s stock worth $202,000 after buying an additional 23 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.79% of the company’s stock.

Key IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Third-quarter results beat expectations: IDEXX reported adjusted earnings of $3.96 per share versus $3.71 expected, while revenue rose about 10% year over year to $1.21 billion, above estimates. Recurring diagnostics sales to veterinarians were a key growth driver. IDXX Q3 Earnings & Revenues Surpass Estimates
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting EPS of $14.96–$15.16, above the $14.86 consensus, and revenue of $4.7–$4.8 billion, versus expectations of about $4.7 billion. The higher forecast reinforces optimism after the quarterly beat. IDEXX raises forecast
• Positive Sentiment: Morgan Stanley maintained an Overweight/Buy view and raised its price target to $810, signaling further potential upside in the analyst’s assessment. Morgan Stanley stock recommendations
• Positive Sentiment: A technical analysis report said IDXX moved above its 200-day moving average, a signal some investors interpret as supportive of a longer-term upward trend. IDXX crossed above the 200-day moving average
• Negative Sentiment: Analysts noted that veterinary visits remain lackluster, creating a challenging demand backdrop. IDEXX’s results were strong despite this, but the company is relying on diagnostics growth to offset softer visit trends. UBS on IDEXX’s results and vet-visit backdrop

IDEXX Laboratories Price Performance

IDXX opened at $672.04 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The company has a 50 day moving average of $538.81 and a two-hundred day moving average of $573.69. The company has a market cap of $52.94 billion, a P/E ratio of 45.38 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter last year, the firm posted $3.22 EPS. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. On average, analysts expect that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on IDXX shares. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Jefferies Financial Group dropped their price target on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research note on Tuesday, October 20th. Citigroup raised their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Barclays cut their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Finally, BTIG Research dropped coverage on IDEXX Laboratories in a research note on Friday, October 30th. They issued a “buy” rating on the stock. Seven investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $719.55.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.